3.1 FD&C Act, Legend vs OTC, Misbranding & Adulteration

3.1 FD&C Act, Legend vs OTC, Misbranding & Adulteration

Minnesota MPJE focus: NABP does not split federal and state items. When federal and Minnesota requirements conflict on a practice question, apply the stricter rule that governs Minnesota practice. The FD&C Act sets the national drug floor; Minnesota Board rules and Minn. Stat. ch. 151 still control day-to-day pharmacy operations.

Why the FD&C Act Matters on the MN MPJE

The Federal Food, Drug, and Cosmetic Act (FD&C Act) of 1938, codified primarily at 21 U.S.C. §§ 301 et seq. and administered by the Food and Drug Administration (FDA), is the backbone of U.S. drug regulation. It governs whether a product may be marketed, how it must be manufactured and labeled, and when it is legally adulterated or misbranded. Minnesota pharmacists do not "enforce" FDA seizures the way FDA investigators do, but they do face Board discipline and civil liability when they dispense misbranded or adulterated products, ignore REMS obligations, or treat an Rx-only drug as if it were OTC.

Landmark amendments you must map to a short trigger and a legal consequence:

Legend (Rx-Only) Versus OTC

Durham-Humphrey framework

The Durham-Humphrey Amendment of 1951 (FD&C Act § 503(b), 21 U.S.C. § 353(b)) created two commercial classes:

1. Prescription (legend / Rx-only) drugs — Unsafe for self-medication because of toxicity, potential for harmful effects, method of use, or collateral measures necessary for use. Must bear the federal legend (modern form: "Rx only" or the standardized Rx symbol) and may be dispensed only pursuant to a valid order of a licensed practitioner.
2. Over-the-counter (OTC) drugs — Safe and effective for lay use when labeled with adequate directions for use and appropriate warnings under FDA OTC monographs or approved applications.

Practice consequences the exam loves

• Dispensing a prescription drug without a valid prescription, or refilling without authorization, is misbranding under federal law—not merely a "technical" state rule violation.
• Switching a product from Rx to OTC (or vice versa) is an FDA regulatory action, not a pharmacist unilateral decision. A pharmacist may recommend OTC therapy within professional judgment but cannot reclassify a legend drug as OTC stock for sale without a prescription.
• Behind-the-counter status (for example, pseudoephedrine quantity/log rules) is a separate federal/state overlay; those products remain non-legend unless FDA places them on prescription status.

Minnesota layers additional label content, counseling, and substitution rules on top of the federal prescription-container exemption—so a fill that meets bare federal § 503(b)(2) elements can still fail Minnesota labeling or counseling standards.

Adulteration Versus Misbranding

Memorize the axis of each violation, then apply scenarios.

Adulteration (composition / conditions)

A drug is generally adulterated when the problem is what the product is or how it was made, stored, or handled, including when it:

• Consists in whole or in part of any filthy, putrid, or decomposed substance
• Was prepared, packed, or held under unsanitary conditions where it may have become contaminated (actual contamination need not be proven)
• Differs in strength, quality, or purity from its official compendial standard or from what it purports to be
• Was manufactured in a facility that fails current Good Manufacturing Practice (cGMP)
• Contains an unapproved color additive or unsafe component

Pharmacy examples: expired product dispensed as current therapy; tablets stored in extreme heat that degrades potency; compounding from filthy equipment; a stock bottle whose strength was diluted by moisture ingress.

Misbranding (labeling / representations / Rx status)

A drug is generally misbranded when the problem is how it is labeled, represented, or dispensed relative to its legal status, including when:

• Labeling is false or misleading in any particular
• It lacks adequate directions for use (for OTC products) or required warnings
• Required manufacturer information, established name, or quantity is missing from commercial packaging
• A prescription drug is dispensed without a valid prescription (or refill authorization)
• Labeling fails to carry the Rx-only designation when required
• Required patient labeling (for example, Medication Guides when mandated) is not provided

Pharmacy examples: wrong directions on the outpatient label; omitting the patient name when required by applicable law; selling an Rx antibiotic "OTC" to a regular customer; commercial package without lot/expiration when required.

Exam trap: The same event can create both adulteration and misbranding (for example, a contaminated product with false purity claims). Choose the best statutory fit the question emphasizes—composition vs labeling.

NDA, ANDA, and Related Pathways (Exam-Level Depth)

Minnesota product-selection statutes and Board rules control when a pharmacist may substitute; the ANDA/Orange Book framework tells you what is therapeutically equivalent at the federal scientific level. Do not confuse "FDA-approved generic" with "automatically substitutable in every Minnesota scenario without counseling or prescriber limits."

REMS Basics

A Risk Evaluation and Mitigation Strategy (REMS) is an FDA-required safety program for certain drugs with serious risks that ordinary labeling cannot adequately manage. Elements can include:

• Medication Guides or patient package inserts
• Communication plans to healthcare providers
• Elements to Assure Safe Use (ETASU) such as prescriber certification, pharmacy certification, restricted distribution, patient enrollment, or documented lab monitoring

Pharmacies that dispense REMS drugs must enroll or certify when required, follow verification steps, and not "work around" restricted networks. On the MPJE, REMS questions test whether dispensing is allowed without the mandated process, not the biochemistry of the drug.

Federal Floor, Minnesota Ceiling

Think of federal FD&C rules as the minimum. Minnesota may require:

• More complete outpatient labels than the six federal statutory elements
• Stricter counseling initiation (Rule 6800.0910—covered in the next section and again in the counseling chapter)
• Board permit, compounding, and return/reuse rules that protect product integrity beyond bare federal adulteration text

If a scenario asks whether a product is adulterated or misbranded under federal definitions, answer with FD&C concepts. If it asks what a Minnesota pharmacist must do before releasing the fill, apply Minnesota Board rules even when federal law is silent.

Section Checkpoint

• Map each landmark amendment to safety, efficacy, or Rx/OTC.
• Sort every fact pattern into adulteration (thing) vs misbranding (words/status).
• Treat REMS and Rx-only status as hard stops, not optional best practices.
• Remember: stricter Minnesota rule wins on practice questions.